PRA International Announces Collaboration with Frontage Laboratories
Complete the form below to unlock access to ALL audio articles.
PRA International has announced a collaborative agreement with Frontage Laboratories Inc. This partnership enables PRA Early Development Services’ US Clinical Pharmacology Center (PRA EDS US CPC) to now offer a full complement of analytical lab testing services to its existing Phase I – IV clinical trial services in North America.
PRA’s 80-bed Lenexa clinical facility near Kansas City, Missouri, runs a multitude of Phase I and Phase IIa studies each year, with a particular focus on first in human studies and other complex PK studies.
By meaningfully broadening its bioanalytical service portfolio, PRA now offers Pharma and Biotech sponsors and other CROs the ability to align the clinical and laboratory processes. It already operates a comparable full-service offering in Europe.
Although PRA conducts clinical trials across a broad spectrum of therapeutic areas, it has a special emphasis in the areas of oncology, central nervous system, allergy/respiratory, cardiovascular disorders and infectious diseases.
Frontage Laboratories Inc. is fully compliant with cGMP/GLP regulations and under this new collaboration will offer specialized bioanalytical services via PRA. The new collaboration also offers pharmacokinetic & biostatistical consultancy and data support.
